biosimilars and oncology clinical pathways: perfect together
Published 4 years ago • 1.8K plays • Length 51:06Download video MP4
Download video MP3
Similar videos
-
5:16
biosimilars: what oncologists need to know
-
16:47
what is needed and what is the role of biosimilars?
-
17:57
understanding biosimilars: differences between biosimilars and reference products
-
23:20
biosimilars for ibd: when to start, switch, or stay away?
-
0:32
the potential of biosimilars in cancer treatment
-
18:00
biosimilars part 1: history and biology
-
38:15
biosimilars and biologics
-
0:54
biosimilars: a promising new therapeutic option in cancer treatment
-
3:00
biosimilars: complex copycat drugs
-
58:36
bispecific antibodies in multiple myeloma
-
3:35
understanding antibody drug conjugates
-
2:04
biosimilars: the path to approval
-
57:41
biosimilars: what's new and what's next 2021
-
19:32
understanding biosimilars
-
6:00
quick guide to biosimilars
-
4:12
the basics of biosimilars
-
44:23
metastatic breast cancer: leveraging clinical pathways to navigate a complex treatment landscape:
-
53:18
utilization of biosimilars: achieving value-based plan management
-
1:24
biosimilars: from science to practice in cancer care course overview
-
3:47
the approval process of biosimilars
-
53:46
biosimilars - impact for patients